Trial Profile
The Risk of Cancer Associated With the Use of Abatacept and Other Biologic Agents Among Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 18 Dec 2018 Planned End Date changed from 31 Dec 2018 to 29 Mar 2019.
- 18 Dec 2018 Planned primary completion date changed from 31 Dec 2018 to 29 Mar 2019.